Dysthyroidism and interferon-alpha: the withdrawal of interferon should not be systematic
Chédin, P.; Cahen-Varsaux, J.; Demmane, S.
Gastroenterologie Clinique et Biologique 19(4): 442-444
1995
ISSN/ISBN: 0399-8320 PMID: 7672530 Document Number: 443410
Document emailed within 1 workday
Related Documents
Balan, V.; Nelson, D.R.; Sulkowski, M.S.; Everson, G.T.; Lambiase, L.R.; Wiesner, R.H.; Dickson, R.C.; Garcia, A.; Moore, P.A.; Yu, R.; Subramanian, G.M. 2006: Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C Antiviral Therapy 11(7): 901-908Shiozawa, S.; Chihara, K.; Shiozawa, K.; Fujita, T.; Ikegami, H.; Koyama, S.; Kurimoto, M. 1986: A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients Clinical and Experimental Immunology 66(1): 77-87
Fischl, M.A.; Uttamchandani, R.B.; Resnick, L.; Agarwal, R.; Fletcher, M.A.; Patrone-Reese, J.; Dearmas, L.; Chidekel, J.; McCann, M.; Myers, M. 1991: A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma Journal of Acquired Immune Deficiency Syndromes 4(1): 1-10
Corbillet, V.; Celerier, P.; Lebon, P.; Litoux, P.; Dreno, B. 1995: Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a Annales de Medecine Interne 146(6): 399-403
Russo, D.; Fanin, R.; Zuffa, E.; Damiani, D.; Gallizia, C.; Michieli, M.; Testoni, N.; Benfenati, D.; Visani, G.; Zaccaria, A. 1990: Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha Haematologica 75(4): 334-339
Koyama, S.; Narita, M. 1988: In vitro effects of interferon-alpha and interferon-gamma on hematopoietic progenitor cells in bone marrow Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 51(8): 1540-1549
Margolick, J.B.; Ambrus, J.L.; Volkman, D.J.; Fauci, A.S. 1986: Human T4+ lymphocytes produce a phagocytosis-inducing factor (PIF) distinct from interferon-alpha and interferon-gamma Journal of Immunology 136(2): 546-554
Mels, G.C.; Roffi, L.; Antonelli, G.; Bellati, G.; Pacchetti, S.; Di Nolfo, M.A.; Panizzuti, F.; Moretti, G.; Piperno, A.; Pozzi, M. 1993: Lymphoblastoid interferon in patients with chronic nAnB hepatitis showing relapse during recombinant alpha interferon therapy Progress in Clinical and Biological Research 382: 359-364
Sayers, T.J.; Wiltrout, T.A.; McCormick, K.; Husted, C.; Wiltrout, R.H. 1990: Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo Cancer Research 50(17): 5414-5420
Ali, S.; Nazir, G.; Khan, S.A.; Iram, S.; Fatima, F. 2010: Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients Journal of Ayub Medical College Abbottabad: Jamc 22(4): 127-130
Grigorian, S.S.; Pritsker, A.D.; Onufrieva, E.K.; Chireshkin, D.G.; Ershov, F.I. 1991: The effect of exogenous interferon on the in vitro production of alpha- and gamma-interferon by the lymphocytes of patients with respiratory papillomatosis Voprosy Virusologii 36(5): 407-409
Perrillo, R.P.; Regenstein, F.G.; Peters, M.G.; DeSchryver-Kecskemeti, K.; Bodicky, C.J.; Campbell, C.R.; Kuhns, M.C. 1988: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial Annals of Internal Medicine 109(2): 95-100
Gustafsson, A.; Sundström, S.; Lundgren, E. 1986: The augmentation of human natural killer cell activity by interferon-gamma is not associated with the induction of the interferon-alpha-inducible proteins Journal of Immunology 137(1): 167-171
Trandafir, L.; Ruffié, P.; Borel, C.; Monnet, I.; Soulié, P.; Adams, D.; Cvitkovic, E.; Armand, J.P. 1997: Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma European Journal of Cancer 33(11): 1900-1902
Sypniewski, D.; Bednarek, I.; Gałka, S.; Loch, T.; Machnik, G. 2008: Influence of interferon-alpha and ribavirin on the transcription of interferon-gamma and IFN-gamma receptor genes in Jurkat cells Acta Poloniae Pharmaceutica 65(3): 345-351
Lvovsky, E.A.; D'Souza, J.; Eng, D.; D'Souza, D.; Lvovsky, B.; Hetland, R.; Craver, W.L.; Sobel, S.H. 1988: Tumor response to interferon inducer and radiation effect of serum interferon levels Journal of Biological Regulators and Homeostatic Agents 2(1): 1-6
Günther, G.; Otto, B. 1993: Interferon. An overview of the state of basic research with special regard to interferon-gamma Arzneimittel-Forschung 43(2): 182-188
Akimoto, M.; Ueki, H.; Nakajima, Y.; Matano, S.; Ewasaki, H.; Abe, R.; Kasai, M. 1984: Prevention of 5-FU induced toxicity in C3 H/HE mice with interferon or with interferon inducers (poly 1: C, OK-432, Lentinan) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(7): 1462-1467
Meager, A.; Parti, S.; Webb, K.; Exley, T. 1986: Development of interferon-specific monoclonal antibody for in vitro interferon assays Developments in Biological Standardization 64: 237-248
Sumpio, B.E.; Ernstoff, M.S.; Kirkwood, J.M. 1984: Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment Cancer Research 44(8): 3599-3603